Register Login

Leap Therapeutics Inc (LPTX)

  • Event
  • July 12, 2022, 11:10 UTC

(10% Negative) Leap Therapeutics, Inc. (LPTX) Announces Delay in disclosed Development Timeline Due to Manufacturing Considerations, Safety Review, Efficacy Assessment

Full text
Register to leave comments
  • News bot Oct. 2, 2025, 12:50 p.m.

    📋 Leap Therapeutics, Inc. (LPTX) - Clinical Trial Update

    Filing Date: 2022-07-12

    Accepted: 2022-07-12 07:10:53

    Event Type: Clinical Trial Update

    Event Details:

    Leap Therapeutics Inc (LPTX) Announces Clinical Trial Update Leap Therapeutics Inc (LPTX) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: disclosed, time
    • Clinical Stage: clinical trial
    • Update Type: Trial Timeline Adjustment
      • expected in Q3 2022
      • targeting colorectal cancer DKK1 elevated in advanced CRC (Tempus) • CRC is characterized by hyperactivation of the Wnt pathway, often believed to be the initiating and driving event • DKK1 drives resistance to 5FU; DKN - 01 has demonstrated prior synergy with 5FU - based regimen in GEA • Preclinically DKN - 01 treatment: • Shows additive activity with 5FU and is able to overcome 5FU - resistance in xenograft models • Has activity alone and with anti - PD - 1 in syngeneic models • Has activity in wild type and PIK3CA mutant models alone and with a PIK3CA inhibitor Stage 1+2 Stage 3+4 T - test, p = 3.9e - 10 DKK1 Expression log2(TPM+1) 9 6 3 0 12 26 DKN - 01 activity in combination with 5 - FU chemotherapy in colorectal cancer models 27 • DKN - 01 has efficacy in CRC syngeneic models including HCT116 • Additive activity was seen with 5FU chemotherapy • In a 5FU chemotherapy - resistant model, DKN - 01 demonstrates significant inhibition of tumor growth Data courtesy of Goel Lab at City of Hope Cancer Center Tumor volume (mm 3 ) HCT116 parental HCT116 5FU - resistant 2500

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval: Not available
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Leap Therapeutics Inc
    • CIK: 0001509745
    • Ticker Symbol: LPTX
    • Period End Date: 2022-07-12
    • Document Type: 8-K

Search

News categories